Full Year 2025 Biomerieux SA Earnings Call Transcript
Key Points
- BioMerieux SA (BMXMF) achieved a significant milestone by reaching EUR4 billion in sales, with a 6.2% organic growth rate, outpacing the market average of around 1%.
- The company reported a strong cash flow generation of EUR460 million, marking a 40% increase compared to 2024.
- The SPOTFIRE point-of-care system saw a substantial improvement in its installed base, with a 110% increase and 3,400 instruments installed in 2025.
- BioMerieux SA (BMXMF) demonstrated strong leadership in Microbiology, achieving a 6.3% growth excluding China, with a 14% increase in instrument sales.
- The company made significant progress on its CSR agenda, reducing CO2 greenhouse gas emissions by nearly 30% since 2019, while sales grew by 50% in the same period.
- The company faced challenges in its immunoassays franchise, with a 6% decline in 2025.
- BioMerieux SA (BMXMF) experienced a decline in China, with a 40% decrease in the market due to pressure from authorities to reduce hospital spending.
- The company reported a net income group share decline of 8% due to the REVEAL impairment and associated charges.
- There is a projected negative currency impact of EUR50 million to EUR60 million on CEBIT for 2026 due to the strength of the euro.
- The respiratory panels segment is expected to face challenges, with a projected growth range of -3% to +3% in 2026, impacted by a high comparison basis from Q1 2025.
Welcome to the bioMerieux 2025 third-quarter sales conference call. The call will be structured in two parts. First, a presentation by bioMerieux Group management team. Afterwards, there will be a Q&A session. (Operator Instructions)
I will now hand over to Aymeric Fichet, VP, Investor Relations. Please go ahead.
Thanks. Hello, everyone. Good afternoon, good morning, and thank you for joining this call. I'm with Pierre Boulud, CEO; together with Guillaume Bouhours, CFO.
Please note that this conference call will include forward-looking statements that may change or be modified due to uncertainties and risks related to the company's environment. Accordingly, we cannot give any assurance as to whether we will achieve these objectives. I also remind you that today's call is recorded and that the replay will be available on our website, www.biomerieux-finance.com.
I will now hand the call
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
